Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Why the study?
Additional data were needed regarding the effect of empagliflozin on inpatient and outpatient events reflecting worsening heart failure in patients with HFrEF, with or without diabetes.
Does empagliflozin reduce inpatient and outpatient worsening heart failure events in patients with class II to IV heart failure with an ejection fraction of ≤40%?
Population
3730 patients with class II to IV heart failure and ejection fraction ≤40%
Comparison
Empagliflozin (10 mg once daily) vs placebo, added to recommended heart failure treatments
Design
Double-blind randomized controlled trial
Follow-up
Median of 16 months
Authors
Discussion
Loading...
Member takes
Implication
Supports empagliflozin as standard in HFrEF; extends prior RCT evidence to outpatient worsening events.
Structured PICO
Does empagliflozin reduce inpatient and outpatient worsening heart failure events in patients with class II to IV heart failure with an ejection fraction of ≤40%?
P
Population
3,730 patients with class II to IV heart failure with an ejection fraction of ≤40%
I
Intervention
Empagliflozin 10 mg once daily, in addition to recommended treatments for heart failure
C
Comparator
Placebo, in addition to recommended treatments for heart failure
O
Outcome
Inpatient and outpatient events reflecting worsening heart failure (individual and composite end points)composite
Empagliflozin significantly reduces both inpatient and outpatient worsening heart failure events in patients with HFrEF, with benefits seen early and sustained over time.
Cite This Study
Packer et al. (2020) studied this question.